Peptides, short chains of amino acids, have been investigated for their potential to modulate immune responses in autoimmune disorders. Scientific research, primarily in preclinical studies and some early-phase clinical trials, suggests that certain peptides can influence immune cell activity, reduce inflammation, and promote immune tolerance. For example, peptide-based therapies have been explored in conditions like multiple sclerosis (using myelin-derived peptides), type 1 diabetes, and rheumatoid arthritis. The rationale is that specific peptides can retrain the immune system to recognize self-antigens as non-threatening, thereby reducing autoimmune attacks.

Despite these promising mechanisms, clinical evidence remains limited. Most studies to date have been small, preliminary, or conducted in animal models. There are a few peptide drugs (such as glatiramer acetate for multiple sclerosis) that are approved and widely used, lending some support to the concept. However, the broader use of generic "peptides" as supplements or treatments for autoimmune disorders lacks robust clinical validation. Larger, well-designed human trials are needed to fully establish safety and efficacy for various peptide therapies in autoimmune disease.

In summary, while there is a scientific basis and some early evidence for the use of specific peptides in treating autoimmune disorders, the overall quality and quantity of evidence is modest, and most peptide-based approaches remain investigational.